CCKBR and medullary thyroid gland carcinoma: This minigastrin-derived truncated peptide has demonstrated clinical utility in both advanced medullary thyroid cancer and small cell lung cancer.19,20 In parallel, we have independently developed our innovative gastramide series of CCK2R-targeting compounds, which represents a distinct approach to this therapeutic space and will be comprehensively evaluated in this study.